George Cusatis
Johns Hopkins University · 22 works · 1,341 citations · h-index 11
Top works
- An In vivo Platform for Translational Drug Development in Pancreatic Cancer
- Pharmacogenetics of ABCG2 and Adverse Reactions to Gefitinib
- Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients
- Pharmacogenetic Pathway Analysis of Docetaxel Elimination
- Effect of CommonCYP3A4andCYP3A5Variants on the Pharmacokinetics of the CytochromeP450 3A Phenotyping Probe Midazolam in Cancer Patients
- Germline Polymorphisms in EGFR and Survival in Patients With Lung Cancer Receiving Gefitinib
- Pharmacogenomic Importance of ABCG2
- Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay
- Stromal Cell-Derived Factor 1α Mediates Resistance to mTOR-Directed Therapy in Pancreatic Cancer
- Development of two novel benzoylphenylurea sulfur analogues and evidence that the microtubule-associated protein tau is predictive of their activity in pancreatic cancer
- Analysis of biologic surrogate markers from a Children's Oncology Group Phase I trial of gefitinib in pediatric patients with solid tumors
- Population pharmacokinetic (PK)-pharmacodynamic (PD) model for gefitinib in cancer patients
- Association of germline mutations in EGFR and ABCG2 with gefitinib response in patients with non-small cell lung cancer (NSCLC)
- In vivo testing of Mycophenolic acid (MPA) in primary pancreatic cancer (PaCa) xenografts
- Pharmacodynamic-guided, modified continuous reassessment method (mCRM)-based, dose finding study of rapamycin in adult patients with solid tumors
- Supplementary Table 1 from An In vivo Platform for Translational Drug Development in Pancreatic Cancer
- Data from An In vivo Platform for Translational Drug Development in Pancreatic Cancer
- Supplementary Table 1 from An In vivo Platform for Translational Drug Development in Pancreatic Cancer
- Combined EGFR targeted therapy in a novel in vivo pancreas cancer model
- Data from An In vivo Platform for Translational Drug Development in Pancreatic Cancer